Review

Myelin Defects in Niemann–Pick Type C Disease: Mechanisms and Possible Therapeutic Perspectives

Antonietta Bernardo 1,†, Chiara De Nuccio 2,†, Sergio Visentin 1, Alberto Martire 1, Luisa Minghetti 2, Patrizia Popoli 1 and Antonella Ferrante 1,*

1 National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy; antonietta.bernardo@iss.it (A.B.); sergio.visentin@iss.it (S.V.); alberto.martire@iss.it (A.M.); patrizia.popoli@iss.it (P.P.)
2 Research Coordination and Support Service, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy; chiara.denuccio@iss.it (C.D.N.); luisa.minghetti@iss.it (L.M.)
* Correspondence: antonella.ferrante@iss.it; Tel.: +39-06-49902050
† These authors contributed equally.

Abstract: Niemann–Pick type C (NPC) disease is a wide-spectrum clinical condition classified as a neurovisceral disorder affecting mainly the liver and the brain. It is caused by mutations in one of two genes, NPC1 and NPC2, coding for proteins located in the lysosomes. NPC proteins are deputed to transport cholesterol within lysosomes or between late endosome/lysosome systems and other cellular compartments, such as the endoplasmic reticulum and plasma membrane. The first trait of NPC is the accumulation of unesterified cholesterol and other lipids, like sphingosine and glycosphingolipids, in the late endosomal and lysosomal compartments, which causes the blockade of autophagic flux and the impairment of mitochondrial functions. In the brain, the main consequences of NPC are cerebellar neurodegeneration, neuroinflammation, and myelin defects. This review will focus on myelin defects and the pivotal importance of cholesterol for myelination and will offer an overview of the molecular targets and the pharmacological strategies so far proposed, or an object of clinical trials for NPC. Finally, it will summarize recent data on a new and promising pharmacological perspective involving A2A adenosine receptor stimulation in genetic and pharmacological NPC dysmyelination models.

Keywords: Niemann–Pick type C disease; myelination; oligodendrocytes; cholesterol; mitochondrial impairment; A2A R; adenosine

1. Introduction

Niemann–Pick disease belongs to the vast section of lysosomal storage disorders (LSD), which includes various inherited metabolic diseases caused by the deficiency of one of the different lysosomal functions [1]. The term Niemann–Pick disease refers to a group of diseases (type A, type B, and type C) whose common denominator is a genetically determined altered function of lysosomal proteins. Mutations in the SMPD1 gene cause Niemann–Pick disease types A and B. They produce a deficiency in the lysosomal enzyme acid sphingomyelinase activity that breaks down the lipid sphingomyelin in ceramide and phosphorylcholine. Failure or insufficient functioning of this enzyme will result in an accumulation of sphingomyelin [2]. Niemann–Pick type C (NPC), on the other hand, is caused by the mutation in the NPC1 and NPC2 genes located on chromosome 18 (locus 18q11-q12) and 14 (locus14q24.3), respectively. The NPC1 gene encodes a protein located in membranes of late endosome/lysosome compartment (LE/L) the NPC2 encodes a protein that binds and transports cholesterol, and it has been shown to closely interact with NPC1. Genetic mutations in the NPC1 gene cause approximately 95% of NPC cases, and 5% are caused by mutations in the NPC2 gene. Mutations in both genes are responsible for a defect in intracellular transport of endocytosed cholesterol that results in the sequestration of
unesterified cholesterol, sphingosine, glycosphingolipids, and sphingomyelin in the LE/L
compartment of various tissues of the body, including the brain [3]. Transmission of the
disease occurs in an autosomal recessive manner. NPC affects an estimated 1–9:100000
people (https://www.orpha.net/ accessed on 16 August 2021). It is classically a neuro-
visceral condition with a wide clinical spectrum. The principal clinical symptoms are
hepatosplenomegaly, jaundice, and fetal hydrops with rapid death often due to hepatic
and respiratory failure; other symptoms include hypotonia, delayed motor development,
speech delay, cataplexy, cognitive impairment, dystonia, and psychiatric symptoms such as
hallucinations and schizophrenia. Common signs of many patients are also ataxia, dyspha-
gia, and vertical supranuclear gaze palsy [4]. NPC can arise at any age and a correlation
exists between the age of onset and the severity of the disease; an early onset of clinical
symptoms is associated, in fact, with a more rapid progression. At the cellular level, NPC
is characterized by lysosomal accumulation of multiple lipids, such as sphingosine, gly-
cosphingolipids, sphingomyelin, and especially cholesterol. The lysosomal accumulation
of lipids and the subsequent inhibition of calcium uptake into the acidic compartment
could result in an unbalance in autophagic flux, with an impaired fusion of late-endosomes
and lysosomes [5,6]. Another classical feature of NPC is the accumulation of cholesterol in
mitochondria. The increase in mitochondrial cholesterol can contribute to mitochondrial
dysfunction and subsequent oxidative stress associated with the disease [7]. Furthermore,
defective mitophagy and increased mitochondrial fragmentation could perpetuate mito-
chondrial dysfunction in NPC due to impaired mitochondrial turnover. Although all NPC
cells show a defect in cholesterol accumulation, the major clinical impact is on the liver and
brain. Cholesterol is particularly enriched in the brain, where it is involved in key biological
functions, such as signal transduction pathways, myelin formation, and synaptogenesis. In
the brain, the most severe consequences of NPC1 mutations are neurodegeneration (due to
the massive loss of Purkinje neurons in the cerebellum and the diffuse atrophy in other
brain regions such as the hippocampus), neuroinflammation, and dysmyelination [8,9].
Herein, we will focus on myelin defects and the efforts made by research to identify and
validate new therapeutic approaches to rescue from these debilitating events.

2. Cholesterol in Myelination

Cholesterol is an essential component of the central nervous system (CNS) and the
peripheral nervous system (PNS). In the CNS, it derives almost exclusively from the
endogenous synthesis since circulating cholesterol is unable to cross the blood–brain barrier
(BBB). Nevertheless, some lipoproteins, sterols, or other circulating molecules could enter
the brain to deliver cholesterol [10]. About 80% of its brain content resides in myelin [11]
where it is a key structural component necessary for the assembling and compacting
of membranes so that the proper electrical insulation of neuronal axons is ensured [12];
cholesterol content influences also membrane fluidity, which in turn may influence myelin
membrane spreading [12]. Indeed, its incorporation in myelin is rate-limiting for membrane
growth [13].

Most of the cholesterol needed for the organization of myelin sheaths during postnatal
myelination is synthesized by oligodendrocytes (i.e., the myelinating cells in the CNS, OLs)
via the isoprenoid biosynthetic pathway [13,14]. Interestingly, cholesterol also regulates the
expression of genes that encode myelin proteins necessary for the differentiation of OLs
from progenitor cells, unable to form myelin leaflets, to mature myelinating OLs [15]. The
molecular mechanism connecting cholesterol to gene expression is based on its ability to
organize membrane microdomains necessary for signal transduction that promotes myelin
gene expression [12]; in particular, the activity of the mechanistic target of rapamycin
(mTOR) kinase, a major driver of myelination by OLs, requires cholesterol to induce myelin
gene expression [12].

It is clear that cholesterol plays a key role in regulating OL functions and, consequently,
the myelination process; this implies that a simple shift in the complex equipment of
synthesis, assembly, or transport of this molecule is enough to activate pathologies of
various orders and degrees. Table 1 collects some hypomyelinating diseases related to the altered functionality of cholesterol itself, considering three main events: biosynthesis, transport, or accumulation. For example, Smith–Lemli–Opitz syndrome, Peroxisome biogenesis disorder, Greenberg dysplasia, and Conradi–Hunermann syndromes are linked to mutations in genes coding for enzymes (7-dehydrocholesterol reductase—DHCR7, acyl-CoA oxidase 1-ACOX1, 3 b-Hydroxysteroid 8, 7-sterol isomerase) involved in the synthesis of cholesterol, and all four commonly lead to reduced myelin formation that clinically manifests itself in developmental delay, motor dysfunction, and more (for further details, specific references are indicated in the table).

For the focus of this review, particularly interesting is the observation that transport defects and intracellular accumulation of cholesterol are accompanied by myelin defects in many disorders. For example, the low-density lipoprotein receptor-related protein-1 (Lrp1), a member of the LDL receptor family with prominent functions also in endocytosis, regulates cholesterol homeostasis in OLs [16] and the differentiation of OL progenitor cells (OPs) [17]. This protein can be defective in some demyelinating diseases, such as peroxisome biogenesis disorders. In Pelizaeus–Merzbacher disease (PMD), missense mutations, duplications, and triplications in the X-linked proteolipid protein (PLP1) gene lead to hypomyelination, progressive loss of oligodendrocytes, and neurodegeneration. PLP1 associates with cholesterol to regulate its enrichment in myelin membranes [13,18,19]; its variants are misfolded and have a reduced ability to bind cholesterol; this causes their retention in the endoplasmic reticulum (ER) likely driving dysmyelination [15].

As mentioned in the introduction and as shown in Table 1, NPC is also conceived as a lipid trafficking disorder [20,21] in which mutations in both NPC1 and NPC2 genes are responsible for a block in intracellular processing of endocytosed cholesterol [20]. Both NPC1 and NPC2 are cholesterol-binding proteins, but the first resides in the membrane of LE/L, and the latter is found soluble in its lumen [22]. Functional studies have led to a “hand-off” model whereby cholesterol present in LE/L compartment is passed from the soluble NPC2 protein to the membrane-bound NPC1 [23]; then, cholesterol is moved toward ER or plasma membrane through a not fully elucidated mechanism that could involve vesicular transport [24]. This defect in cholesterol transport results in its sequestration in the LE/L compartment, which secondly decreases its content in the plasma membrane [25]. During active myelination, selected myelin proteins in OLs are transported together with cholesterol through LE/L compartment for lipid remodeling involving NPC1 and NPC2 proteins [9,26]. Thus, it is not surprising that the mutations in these proteins occurring in NPC are associated with myelin defects in patients and mouse models of disease. Pathological hallmarks of such defects will be described in the following section and the cellular mechanisms driving hypomyelination will be highlighted.

### Table 1. Hypomyelinating diseases connected to cholesterol metabolic processes alterations.

| Main Events in Cholesterol Metabolism | Defective Protein | Impairment | Hypomyelinating Diseases | References |
|--------------------------------------|-------------------|------------|--------------------------|------------|
| Synthesis                            | 7-dehydrocholesterol reductase | abnormality in cholesterol production | Smith-Lemli-Opitz syndrome | [26,27] |
| Synthesis                            | acyl-CoA oxidase 1 (ACOX1) | very-long-chain fatty acid (VLCFA) accumulation | Peroxisome biogenesis disorder | [28,29] |
| Synthesis                            | 3 b-Hydroxysteroid 8, 7-sterol isomerase | 8,9-unsaturated sterols accumulation | Greenberg dysplasia, Conradi–Hunermann syndrome | [30] |
| Transport                            | ABCA1 transporter, HDL | No transport out cell | Tangier disease | [31] |
| Transport                            | ABCA1, Lrp1 | disrupts cholesterol homeostasis | Peroxisome biogenesis disorder | [16,29] |
| Transport                            | NPC1, NPC2 | defective cellular cholesterol transportation | Niemann–Pick disease C | [26,32] |
Table 1. Cont.

| Main Events in Cholesterol Metabolism | Defective Protein                          | Impairment                                      | Hypomyelinating Diseases                  | References |
|--------------------------------------|--------------------------------------------|-------------------------------------------------|-------------------------------------------|------------|
| Accumulation                         | sterol 27-hydroxylase (CYP27A1)           | abnormal cholesterol accumulation               | Cerebrotendinous xanthomatosis,           | [33,34]    |
|                                      | CYP27A1, Lecithin–cholesterol acyltransferase (LCAT) enzyme, vesicle-associated membrane protein-associated protein B (VapB), and OxySterol Binding Proteins (OSBP) | higher total cholesterol and HDL and LDL levels | Sporadic amyotrophic lateral sclerosis     | [35]       |
|                                      | beta-galactosylceramidase                  | galactosyl-sphingolipids accumulation            | Globoid cell leukodystrophy or Krabbe disease | [36]       |
|                                      | arylsulfatase A (ARSA) and Prosaposin precursor (PSAP) | Sulfatides accumulation                          | Metachromatic leukodystrophy              | [37,38]    |
|                                      | PLP1                                       | co-accumulation of PLP and cholesterol           | Pelizaeus–Merzbacher disease              | [39,40]    |
|                                      | peripheral myelin protein 22 (PMP22)       | co-accumulation of apoE, LRP1, and ABCA1        | Charcot–Marie–Tooth, Dejerine–Sottas syndrome | [41–43]   |

3. Myelin Defects in NPC1

Many clinical pieces of evidence demonstrate myelin defects in patients with NPC. Analysis performed in six adult patients revealed a widespread reduction in white matter compared to age-matched controls indicative of impaired myelination [44]. In another study, diffusion tensor imaging (DTI, a magnetic resonance imaging technique used to measure the diffusion of water in white matter) revealed reduced myelin water fraction (MWF) in the white matter of two adult patients with NPC compared to 15 healthy control subjects [45], indicative of reduced myelination; in addition, the less clinically affected patient showed focal reductions in MWF in the corpus callosum in contrast to the more extensive and widespread reductions across entire fiber tracts observed in the more affected subject. Another 9-year-old patient, affected by a rapidly progressive form of NPC, showed very severe myelin reduction, the extent of which by far exceeds that of neuronal damage [32]. These pieces of evidence argue for the possibility that a correlation exists between the degree of defects in myelination and the progression of the disease, and that the therapeutic targeting of this pathological event could ameliorate the symptoms of NPC. To succeed in this aim, it is necessary to better understand the contribution of each cell type to myelin defects and the cellular mechanisms responsible for it by using animal models recapitulating the pathological hallmarks detected in patients. The NPC mouse BALB/cNctr-Npc1m1N/J, carrying a spontaneous mutation of NPC1 causing a functional loss of NPC1 protein, is frequently used in NPC because it recapitulates many features of the early-onset human disease. Starting from the 1980s, primary dysmyelination of the cerebral cortex and corpus callosum of NPC mice compared to their WT counterparts. Takikita and co-workers [47] observed a markedly reduced number of mature OLs in the cerebral cortex and corpus callosum of NPC mice compared to their WT counterparts. They suggested axonal incapability in receiving myelination due to an inappropriate axon-glial interaction. A deeper insight into the molecular mechanism responsible for the reduction of mature OLs demonstrated that the absence of NPC1 protein could be responsible for the decreased expression of the myelin gene regulatory factor (MRF), a transcriptional factor critical for OLs maturation [48]. Other studies confirmed that the defects observed in the myelination process in NPC are due to an inhibition of OLs maturation rather than to a reduction in their number [49,50], and this mechanism was observed in other models
of NPC; in fact, the NPC1<sup>nmf164/nmf164</sup> mouse strain (characterized by the substitution of aspartate to glycine in NPC1 protein) also shows a decrease in the expression of the myelin basic protein (MBP), a well-established marker of mature myelin, in the cerebellum (the most affected brain area in NPC) [51]. Moreover, the decrease in MBP affected either the 18.5 kDa form of the protein, which is specifically expressed by mature OLs, and the 17.5 and 21.5 kDa forms, which are specific for developing OLs. Studies using a feline model of NPC showed abnormalities also in the peripheral nervous system that was characterized by motor and sensory nerves with decreased myelin thickness and reduced axon diameter [52].

Although OLs are the main actors in the myelination process, it should be recalled that their interaction with neurons and glial cells (both astrocytes and microglia) is pivotal for myelin homeostasis [53]. To dissect the contribution of neurons and OLs to the dysmyelination process, Yu and Lieberman used a conditional mouse model in which the deletion of the NPC1 protein could be restricted to neurons or OLs [9]. Their results demonstrated that neuronal NPC1-knockout mice exhibit the dysmyelination phenotype of global null mutants and that this effect is due to a lack of maturation of OLs; in addition, the deletion of the protein in OLs (which abrogates their ability to utilize cholesterol from the endocytosis of low-density lipoprotein, LDL) causes a similar but less severe defect in myelination. The authors concluded that the entry of exogenous cholesterol inside cells and its trafficking mediated by an NPC1-dependent pathway is a key event for the formation and maintenance of CNS myelin. Moreover, their data suggest that NPC1 deficiency in neurons impairs the axonal-glial signal necessary for correct myelination. Together with neurons, microglia also play an important role in the regulation of the myelination process; among their several functions, during brain development, microglia are responsible for the recruitment of OPs and their differentiation, and the clearance of myelin debris [54,55]. Considering that an impairment of removal of myelin debris can compromise the re-myelination process after injury, it can be supposed that a defect in microglial functions can play a role in the dysmyelination occurring in NPC. Indeed, in a very elegant paper from Colombo and co-workers, the authors demonstrated that at a pre-symptomatic stage of disease BALB/cNctr-Npc1m1N/J mice exhibited hyperactive microglia characterized by enhanced phagocytic uptake and aberrant delivery of myelin into lysosomes, as demonstrated by the over-expression of the protein LGALS3, which is involved in microglial phagocytosis of myelin [56]; this caused defects in myelin turnover and the formation of intracellular lipid droplets accompanied by a strong pro-inflammatory phenotype and compromised function. Interestingly, accumulation of LGALS3 was also found in the blood serum of NPC patients, suggesting that the defects found in mouse microglia can be representative of similar impairments in patients. In addition, these results demonstrated that microglial activation is a direct consequence of the loss of NPC1 function in microglia and not an immune response secondary to degenerating neurons. In agreement with these results, Gabande-Rodriguez and co-workers analyzed microglial function in different lysosomal storage diseases [57]. Concerning NPC, in symptomatic NPC1<sup>nmf164/nmf164</sup> mice they found an increased number of microglia in the hippocampus, cortex, and cerebellum; in the latter, microglia were characterized by an amoeboid morphology and were positive to MBP staining, indicative of accumulation of myelin debris. The authors hypothesized that the protective role exerted by microglia in clearing myelin debris is corrupted by lipid overloading occurring in NPC [57].

In conclusion, these results indicate that a defective OLs maturation could trigger a myelination failure in NPC resulting in dysmyelination. In particular, this defect is caused by an impaired differentiation of pre-myelinating OLs into myelinating OLs rather than a reduced differentiation of OPs into premyelinating OLs (Figure 1).
Figure 1. Blocking of oligodendrocyte differentiation in the NPC. Specific markers allow identifying the differentiation status of cells of the oligodendrocyte lineage from progenitors (OPs) to myelinating OLs. The stage when the maturational block due to NPC mutation occurs is indicated. The markers indicated are: A2B5 and GD3 antigens, cell surface gangliosides; NG2, cell surface chondroitin sulfate proteoglycan; PDGFα, platelet-derived growth factor receptor alpha; DM20, a splice variant of the proteolipid protein; CNP, 2',3'-Cyclic-nucleotide 3'-phosphodiesterase; O4 antigen, cell surface sulfatide; O1, galactocerebroside; PLP: proteolipid protein; MBP, myelin basic protein; MAG, myelin-associated glycoprotein; MOG, myelin oligodendrocyte protein.

4. NPC Cellular Defects Potentially Affecting OLs Differentiation

With the intent of offering a view of the main cellular events that could also play a role in dysmyelination occurring in NPC, herein we will describe some cellular defects of NPC and discuss the potential impact on myelin-forming cells (Figure 2). Although very few data have been collected specifically in OLs, some hypotheses can be formulated about the role potentially played by such defective events in the dysmyelination observed in NPC.

Figure 2. Cellular events involved in NPC1 disease: (a) cholesterol accumulation in lysosomes due to the loss of function of the cholesterol (ch) transporter NPC1; (b) autophagy/mitophagy blockade and accumulation of indigested autophago-lysosomes due to lysosomal accumulation of ch, ch-induced hyperactivation of the anti-autophagy complex mTORC1; (c) accumulation of dysfunctional mitochondria due to accumulation of ch in mitochondria and mitophagy blockade; (d) ATP production decrease and ROS increase by dysfunctional mitochondria; (e) loss of lysosomal ionic homeostasis. Blue pentagons: cholesterol.
4.1. How Lysosomal Impairment Affects Mitochondria and OLs Differentiation

Many mitochondrial functions, which are found defective in NPC, are essential for the differentiation of OPs toward mature OLs [58]. Mitochondria supply the energy required for the high metabolic rate of differentiating cells and the synthesis of large amounts of membrane components of myelin, such as cholesterol. Moreover, nuclear and mitochondrial genes coding for mitochondrial proteins are upregulated during OLs differentiation [59].

The primary trait of mitochondrial involvement in NPC is the accumulation of cholesterol in the mitochondrial membranes. Among the secondary events depicting mitochondrial functional demise observed in NPC experimental models are: a decreased mitochondrial ATP production, an increase in mitochondrial ROS and a decrease in the endogenous antioxidant glutathione (GSH), and an increase in fragmented mitochondria due to the unbalance between fission and fusion processes [60]. According to the most accepted view, cholesterol accumulation in mitochondria is due to direct contact sites between endo/lysosomal membranes and mitochondria, which in healthy conditions are involved in substrate entrance in mitochondria to fuel the Krebs cycle and in general to fulfill bioenergetic needs. The accumulation of cholesterol in mitochondrial membranes is associated with a decrease in membrane fluidity and, in turn, to the functional alteration of membrane proteins such as respiratory chain complexes and transporters [61]. Indeed, mitochondrial respiratory chain deficiency and inner membrane depolarization have been detected in mouse models of NPC [62] and fibroblasts from patients [63]; more importantly for the focus of the present review, in primary OLs modeling the maturational arrest characteristic of NPC, mitochondria showed significant morphological and functional impairments [64].

So far, a direct correlation between mitochondrial defects and dysmyelination occurring in NPC has never been investigated, but, given the pivotal role of mitochondria in regulating OLs differentiation, it would be very interesting to address this issue in future in vivo studies.

4.2. How Impairment in Lysosomal Functions Affects Autophagy and OLs Differentiation

Lysosomal functions are directly affected by the decrease in mitochondrial ATP production, which is crucial for the maintenance of the ionic homeostasis in lysosomes (especially of H+ and Ca2+), and the acidic pH in the lysosomal lumen [65]. In turn, acidic pH is needed for the proper activity of hydrolytic enzymes and for the control of lysosomal Ca2+ concentration, which is necessary for vesicle trafficking, fission, and fusion with other organelles [66]. The fusion of lysosomes with autophagosomes in autophagolysosomes is a key event to give rise to the autophagic process necessary for the clearance of unneeded materials [67]. Lysosomes are not only digestive hubs, but they also belong to a network capable to respond to the changing metabolic needs of the cell. One of the pivotal signaling mechanisms involved in the catabolic/anabolic regulation of metabolism is triggered by the nutrient-driven transfer of mammalian Target of Rapamycin complex (mTORC1) from the cytoplasm to the lysosomal membrane, where growth factors activate mTORC1 through of the PI3K-AKT pathway; once activated, mTORC1 drives metabolism toward anabolic reactions and acts as a potent inhibitor of autophagy [68]. Among nutrients capable of activating mTORC1, there are mainly amino acids, glucose, and, importantly for NPC, cholesterol [69].

Calcium, autophagy, and mTORC1 have been found impaired in different models of NPC, as described later on.

A mounting body of evidence demonstrates both a decrease in lysosomal luminal Ca2+ concentration [5,63] and a defect of autophagy in NPC [20]; interestingly, an imbalance in the autophagic flux also in primary cultures of OLs modeling the maturational arrest occurring in NPC [64] was recently demonstrated. As concerning mTORC1, a close interaction exists with cholesterol and NPC1 protein, the first being an activator and the second a repressor of mTORC1 [68]. Mutations in NPC1 protein results in hyper-activation of mTORC1 in NPC disease and, consequently, in autophagy inhibition [68].
If such impairments in autophagy can play a role in the myelin defects observed in NPC has not been investigated. However, the recent observation that autophagy is essential for OLs differentiation and proper myelination [70], and that autophagy was affected in OLs modeling NPC [64], suggests a possible involvement of autophagy in NPC myelin defects. In addition, mTORC1 activity is crucial for the remyelination process, being involved both in the first phase of development of OPs from O4 to pre-myelinating OLs and, in later phases, characterized by increased synthesis of lipids and membrane proteins [71]; moreover, hyper-activation of mTORC1, like the one occurring in NPC, was shown to slow down remyelination [72]. Further studies investigating the role played by the autophagy defect in the maturational arrest of OLs observed in NPC are worth considering.

5. Therapy Perspectives: The State of the Art

As previously shown, the current working model for the molecular mechanisms responsible for the symptomatology of NPC disease, including dysmyelination, is indisputably based on the intracellular accumulation of cholesterol. As shown in the previous section, defects in lipid transport and storage are the cause of many pathological events occurring both in neurons and in OLs. For this reason, the therapeutic interventions that have been explored so far aimed at reducing cholesterol and sphingolipids either by inhibiting their synthesis or by reducing their accumulation. Miglustat (an iminosugar drug that reversibly inhibits the first step in glycosphingolipid synthesis [73]), cyclodextrins (chelators of intracellular cholesterol), arimoclomol (an inducer of HSP70 expression that increases sphingomyelinase activity resulting in reduced accumulation of cholesterol [74]) and vorinostat (a histone deacetylase inhibitor able to increase the expression of NPC1 and reduce cholesterol accumulation [75]) are the main drugs entered in clinical trials. Very few data are present in the literature about their efficacy in reducing dysmyelination in NPC patients. The following sections will focus only on drugs that have been clinically evaluated also for their ability to ameliorate myelin defects.

5.1. Miglustat

The only drug currently approved in the EU and other countries is miglustat [22,76]. Miglustat (OGT 918, N-butyl-deoxynojirimycin) is currently marketed as Zavesca by Actelion Pharmaceuticals. Miglustat was approved in 2002 by EMA and in 2003 by FDA, as a treatment for type 1 Gaucher disease [77]. However, it can be only prescribed off-label in the US, since the FDA did not approve the drug for NPC treatment, being considered to have insufficient proof of efficacy [78], and given the adverse gastrointestinal effects [79,80]. Despite the approval, the EMA overview document of Zavesca also describes the response to the drug treatment of patients in clinical trials as limited to a slight improvement in swallowing ability and intellectual function, and to a stabilization/decrease in the rate at which symptoms worsened in about three-quarters of the treated individuals (https://www.ema.europa.eu/en/documents/overview/zavesca-epar-summary-public_en.pdf, accessed on 16 August 2021). Few data concerning the effect of miglustat on myelin defects in patients are available. It is worthy of note that one year of miglustat therapy improved fractional anisotropy (FA), a marker of axonal myelin integrity assessed by neuroimaging, in the corpus callosum of an adult NPC patient [81]. Recently, a revision of the effectiveness of miglustat was performed by assessing a range of measures and by also evaluating its effect on myelin [82]. Diffusion tensor imaging (DTI), used to measure white matter architecture and integrity, revealed that miglustat improved the FA in the corpus callosum after 1 year of therapy. Another prospective study in a cohort of 13 patients also demonstrated improvement of FA in the corpus callosum, forceps minor, and cingulate gyrus after 2 years of treatment. This study demonstrates that miglustat can improve neurological symptoms of NPC patients also by delaying the progression of the dysmyelination process [82].
5.2. Cyclodextrins

The reduction in the cholesterol load in cells exerted by cyclodextrins allows redistribution of the cholesterol from the late endosome/lysosome compartment to the extracellular space [83]. Even though the mechanism behind cyclodextrin functioning is not fully understood, the efficacy of the cyclic oligosaccharide 2-hydroxypropyl-β-cyclodextrin (HPβCD, a cholesterol-chelating agent) has been extensively demonstrated in NPC experimental models [83–85]. Preclinical studies showed promising results, such as the delayed onset of neurological symptoms and increased lifespan [22]. Consequently, many clinical trials were initiated with HPβCDs. One of these investigational products is the VTS-270 produced by Mallinckrodt Pharmaceuticals; in this phase 2/3 trial (ClinicalTrials.gov Identifier: NCT02534844), NPC patients were administered by the lumbar intrathecal route with 900–1800mg of the drug every 2 weeks. Unfortunately, in January 2021 it was discontinued from its clinical development in NPC patients because of a negative benefit/risk balance (https://www.inpda.org/wp-content/uploads/2021/01/MNK-Announcement-INPDA-Jan-2021.pdf, accessed on 16 August 2021). Another HPβCD, under the name of Trappsol® Cyclo™, obtained promising clinical results about its efficacy for both systemic and neurologic manifestations of NPC [86] and is going to be evaluated in a phase III study (NCT04860960), in which it is intravenously injected in patients at the dose of 2000mg/kg every 2 weeks. Since HPβCD intravenously administered has a short biological half-life [87] and does not easily pass the blood–brain barrier (BBB) [88], strategies to increase the fraction of the drug reaching the brain are currently under evaluation (PREPRINT: Carrasso et al., bioRxiv 2020.07.31.230136; doi: https://doi.org/10.1101/2020.07.31.230136, accessed on 16 August 2021). At least to our knowledge, no extensive clinical evaluation of the impact of HPβCD on dysmyelination is available. However, some preclinical results demonstrated that methyl-β-cyclodextrin administration in NPC mice increased myelination [89], partially rescued lipid droplet formation, and restored the homeostasis of microglia, supporting the idea that cholesterol-lowering in NPC can be beneficial also against the perturbation of microglial functions that contribute to the dysmyelination process [56].

6. Pharmacological Advance in the Development of New Targets: Preclinical Studies

Despite the many potential molecular targets for the improvement of myelin defects in NPC, very few drug candidates have entered in clinical trials. Indeed, finding an effective cure for NPC is extremely challenging for many reasons: (i) treatments should be efficacious in both the brain and peripheral organs (i.e., liver and spleen); (ii) early diagnosis is unusual and thus, the therapy initiates after neuronal death and hypomyelination have (sometimes irreversibly) progressed; (iii) being an ultra-rare disease, finding a sufficient number of patients with similar disease severity is very difficult.

Nevertheless, many efforts in the field are in progress to find new “druggable” targets, such as replacement therapies aimed at transferring the NPC1 gene in mice, which indeed improved behavioral abnormalities and increased their lifespan [90–92]. Neither these studies nor others evaluated the impact of the treatment on myelin defects. Nonetheless, N-Acetyl-L-Leucine, a derivative of the branched-chain amino acid leucine, significantly reduced neuroinflammation and lipid storage in NPC1-/- mice [93]. More interestingly for the focus of this review, a protective effect of N-Acetyl Cysteine was observed in OPs both in vitro, in terms of suppression of apoptosis and in vivo, as attenuation of motor impairment and white matter dysmyelination in the corpus callosum [94]. A Phase II study (NCT03759639) is currently assessing the safety and efficacy of N-Acetyl-L-Leucine (IB1001) for the treatment of NPC.

Another potential drug tested in preclinical models of NPC is lovastatin, an inhibitor of 3-hydroxy-3-methylglutarlyl-coenzyme A (HMG-CoA) reductase, which was evaluated for its ability to induce differentiation of OLs derived from a mouse model of NPC; the results showed that it inhibited cholesterol synthesis, reduced its accumulation in endo-lysosomes, and increased the maturation of NPC OLs [49].
The neurosteroid allopregnanolone was tested as well in mouse models of NPC [95]. The rationale for testing allopregnanolone resides in the observation that sequestration of cholesterol inside cells would alter neurosteroidogenesis and contribute to the neuropathology of NPC [96]. Indeed, allopregnanolone levels are found decreased in NPC [95]. The beneficial effects of allopregnanolone on dysmyelination, alone or in combination with HPβCD and miglustat, have been extensively investigated in NPC mice [95,97,98]. Specifically, the administration of allopregnanolone solubilized in HPβCD to NPC mice was effective in delaying clinical onset, extending lifespan, and reducing ganglioside accumulation [95]; moreover, this treatment also normalized myelin content in the corpus callosum and hippocampus measured by DTI [89]. However, considering that in the above-mentioned studies allopregnanolone was dissolved in HPβCD that as such is beneficial in NPC, it is possible that the myelination process promoted by the treatment is not due to allopregnanolone but rather to its vehicle HPβCD. Indeed, Davidson found that the combination therapy of miglustat with allopregnanolone dissolved in HPβCD ameliorated the NPC disease, but also the vehicle (HPβCD) provided significant benefits; on the contrary, allopregnanolone without HPβCD did not appear beneficial [99]. Similar results were obtained also by Liu and co-workers who found that HPβCD prolonged the average life of NPC mice (>108 days), but the addition of allopregnanolone had no additive effects [84].

Among new therapeutic targets under preclinical evaluation in NPC models, our group focused on the neuromodulator adenosine, which will be described in detail in the following section.

7. Role of Adenosine and Adenosine A<sub>2A</sub> Receptors in NPC

Adenosine is a nucleoside ubiquitously distributed throughout the body and a paracrine homeostatic modulator of different cellular functions. In the CNS, adenosine plays an important role in controlling synaptic plasticity, cognition, sleep, motor function, and neuronal survival [100]. Its levels are finely tuned by the orchestrated action of enzymes and transmembrane transporters (ENTs) that ensure the physiological level of extracellular adenosine necessary to exert its proper receptor-dependent and -independent pathways [101]. In particular, four G-protein-coupled receptors are mainly involved in its signaling: A<sub>1</sub>, A<sub>2A</sub>, A<sub>2B</sub>, and A<sub>3</sub> [102,103]. Among them, the A<sub>2A</sub> receptors (A<sub>2ARs</sub>) seem to have particular relevance in NPC. These receptors, which are mainly coupled to Gs resulting in AC-cAMP-PKA pathway activation, play a major role in the brain, being effective modulators of neuronal damage in various pathological situations, and both their activation and blockade are known to result in being neuroprotective in different experimental conditions, probably involving multiple concerted actions [104–107]. Although A<sub>2ARs</sub> are most abundant in the striatum, they are also present in the hippocampus, where they finely modulate synaptic transmission and excitotoxicity [108], and in the cerebellum, where their function is still poorly characterized, being these brain areas, both affected in NPC.

Furthermore, the importance of keeping the levels of brain adenosine to an appropriate physiological level is demonstrated by the observation that a deregulated signaling was found in many neurodegenerative diseases such as Alzheimer’s disease (AD), epilepsy, and Huntington’s disease (HD), and the enhancement of adenosine levels in these pathological conditions was found beneficial [109,110]. Adenosine plays a pivotal role also in modulating the myelination process as demonstrated by its ability to affect migration, proliferation, and maturation of oligodendroglial cells. As comprehensively described in previous reviews, its action on OLs depends on the receptor subtype that is stimulated [111]. Of particular interest for the present review is the role played by the adenosine receptor A<sub>2A</sub> both in the myelination process and in the NPC pathology. The group of Coppi and co-workers characterized the function of A<sub>2AR</sub> in OPs by demonstrating that in vitro stimulation of the receptors with the selective agonist CGS21680 delayed their differentiation into OLs without affecting cell viability [112]; in addition, the A<sub>2AR</sub> antagonist SCH58261 in zebrafish larvae induced OPs migration from
motor exit point in the transition zone [113]. These results demonstrate that A$_{2A}$R can modulate both the differentiation and the migration of OPs.

Concerning NPC, different evidence indicates an imbalance of the adenosine signaling: first, a reduced level of adenosine has been consistently shown in the brain of NPC1-/mice [114] that could be responsible for the impaired synaptic plasticity observed in this model and, as a consequence, for their cognitive deficits. As a consequence of adenosine reduction, the signaling mediated by its receptors could be impaired; in fact, different in vitro and in vivo studies in our lab demonstrated that the stimulation of the A$_{2A}$ receptors was able to restore a normal phenotype in NPC cellular models. We first demonstrated that in fibroblasts from NPC1 patients the A$_{2A}$R stimulation by the agonist CGS21680 restored lysosomal calcium content, mitochondrial membrane potential (mMP), and cholesterol distribution [63]. The use of fibroblasts from NPC patients is relevant but, considering the major involvement of the CNS in NPC pathology, it is important to test drugs also in cellular models representative of the cellular abnormalities affecting neuronal and glial cells. For this reason, we performed experiments in neuronal and oligodendroglial cell lines of human origin and we induced the NPC1 phenotype by small-interference RNA. As we had already observed for fibroblasts, also in “CNS cell lines” the A$_{2A}$R stimulation by CGS21680 was effective in reducing cholesterol accumulation and in normalizing mitochondrial membrane potential [115]. These results paved the way for the next in vivo studies, in which NPC1-/mice were treated with the compound T1-11 that can weakly stimulate A$_{2A}$R and increase the level of adenosine in the brain by inhibiting its transporter ENT1. The drug significantly ameliorated the cognitive deficits of mice, reduced Purkinje neuron loss and sphingomyelin accumulation in the liver, and extended their survival [116].

Given the modulatory role of A$_{2A}$R in the differentiation of OLs and considering that a delay in oligodendroglial maturation seems to be the cause of the dysmyelination pathology in NPC disease, we decided to analyze the impact of its stimulation on OPs maturation [64]. To this aim, we exposed primary cultures of OPs to U18666a, an inhibitor of cholesterol transport usually used to induce an NPC-like phenotypes in vitro [80]. As expected, U18666a induced typical features of NPC1 phenotype such as intracellular accumulation of cholesterol, abnormal mitochondrial depolarization, and impaired autophagy. Moreover, it caused a maturational arrest of OPs as demonstrated by the decrease in the percentage of O$_{4}$ (immature OLs) or MBP (non-myelinating mature OLs)-positive cells. The treatment with CGS21680 overcame the maturation arrest (demonstrated by the increase in the percentage of O$_{4}$, O$_{1}$ and MBP expressing cells) induced by U18666a and restored the complex, arborized morphology of cells [64]. Interestingly and in agreement with Coppi and co-workers, in control cultures (i.e., in absence of U18666a) CGS21680 induced an arrest in OLs differentiation as indicated by the decrease in the percentage of O$_{4}$ and MBP expressing cells [112]. The opposite effect of A$_{2A}$R stimulation in healthy and in NPC1 cells could indicate a profound functional change of this receptor induced by intracellular cholesterol accumulation and by its consequent depletion in the membrane. Indeed, a reduction in membrane cholesterol concentration such that occurring in NPC [117] can inhibit the activity of A$_{2A}$R as indicated by the reduction in cyclic adenosine monophosphate (cAMP) production [118]. Such a “double-faced effect” of A$_{2A}$R stimulation has been already observed in other pathological conditions such as in HD; in fact, in HD mice (the R6/2 model) CGS21680 potentiated the toxicity induced by NMDA receptor stimulation in WT mice but attenuated it in HD littermates [119]. Thus, we can hypothesize that in physiological conditions, an overactivation of the receptor can result in a maturation arrest of OLs, but the lysosomal entrapment of cholesterol caused by U18666a, can reduce its tonic activation; consequently, receptor stimulation exerted by CGS21680 can restore the basal signaling necessary for the proper maturation of OLs. Together with the beneficial effect observed on differentiation of OLs, our data also demonstrated that the stimulation of A$_{2A}$Rs reduced intracellular cholesterol accumulation, mitochondria abnormalities and rescued from the unbalanced autophagic flux induced by U18666a in OPs (Figure 3) [64].
Figure 3. CGS21680 restores oligodendrocyte functions and differentiation in the NPC-like pharmacological culture model. The A2AR agonist CGS21680 counteracts the effects induced by the cholesterol transport inhibitor U18666A, known to induce an NPC-like phenotype: (a) by reducing the accumulation of cholesterol, as shown by the cholesterol probe Filipin III; (b) by restoring the autophagic flux, as evidenced by normalization of LC3 and LAMP2 markers (*p < 0.05 vs CTR; **p < 0.05 vs U18666A); (c) by normalizing mitochondrial morphology and membrane potential; (d) by counteracting the maturation arrest and favoring OLs differentiation toward cells responsible for myelin formation. Green and red lines illustrate CGS21680 and U18666A effects, respectively; arrows and truncated lines indicate positive and negative effects, respectively.

In conclusion, these data suggest that the stimulation of A2AR could represent a promising therapy for NPC disease because it can simultaneously impinge on many pathological events such as cholesterol accumulation, mitochondrial dysfunction, autophagy, and OLs differentiation.

8. Conclusions

Preclinical research in NPC is at an earlier stage relative to other neurodegenerative disorders, struggling with the complexity of the molecular abnormalities observed in NPC experimental models and the consequent poor translation to the clinical setting [120]. Looking on the bright side, the knowledge of the molecular pathways contributing to the NPC pathophysiology is rapidly increasing, and considerable knowledge has emerged from the preclinical studies conducted so far, in vitro and in vivo, in NPC models. Like for all the orphan disorders, clinical research in NPC is a challenging task, since its rarity does not allow to conduct large clinical trials. The difficulties are also related to the lack of early diagnosis of NPC in many young patients, and to the fact that the treatment should be effective in both the brain and visceral organs. For these and other reasons, no effective treatment, except for miglustat, is currently available for the NPC disease. Among the different outcome measures used in NPC preclinical and clinical studies, dysmyelination is one of the newest, and more interesting, phenotypes considered (see Table 2 for a summary), since it is a feature of NPC in both patients and animal models [44]. The increase in adenosine levels and A2AR stimulation could represent therapy perspectives in NPC, considering their beneficial effects on dysmyelination.
Table 2. Drugs evaluated in NPC and their effects on dysmyelination.

| Drug                          | Main Mechanism of Action                                      | Phase (or Clinical Use if Applicable) | Effect on Dysmyelination (Preclinical)                                      | Effect on Dysmyelination (Clinical)                  | References |
|-------------------------------|---------------------------------------------------------------|---------------------------------------|--------------------------------------------------------------------------------|------------------------------------------------------|------------|
| Miglustat                     | Glycosphingolipid synthesis inhibition                       | Approved by the EMA for clinical use in NPC Prescribed off-label in the US | no data available                                                               | Improvement of fractional anisotropy (FA)             | [81,82]    |
| Hydroxypropyl-β-cyclodextrin (HPβCD) | Cholesterol chelation and redistribution          | phase III, ongoing                    | Increased myelination, rescued lipid droplet formation, restored homeostasis of microglia | Improvement in fine and gross motor functions, and swallowing | [56,85,88] |
| N-Acetyl-L-Leucine             | Neuroinflammation Reduction                                 | phase II, ongoing                     | Protective towards oligodendrocyte progenitor cells in models of neonatal hypoxic-ischemic encephalopathy (HIE) | no data available                                    | [93]       |
| Lovastatin                    | Inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) dehydrogenase | none                                  | Reduced cholesterol accumulation and increased the maturation of NPC OLs          | no data available                                    | [49]       |
| Allopregnanolone              | Neurosteroid deficient in NPC mice                         | none                                  | In NPC mice, allopregnanolone solubilized in HPβCD delayed clinical onset, extended lifespan, reduced ganglioside accumulation, normalized myelin content | no data available                                    | [88,94–97] |
| CGS21680                      | Adenosine A2A receptor agonist                             | none                                  | Overcame the OP maturation arrest, restored the morphology of cells, reduced cholesterol accumulation, mitochondria abnormalities, and protected OP from the unbalanced autophagic flux | no data available                                    | [64]       |

Author Contributions: Conceptualization, A.F., A.B., S.V., C.D.N. and A.M.; writing—original draft preparation, A.F., A.B., S.V., C.D.N. and A.M.; writing—review and editing, A.F., A.B., S.V., C.D.N., A.M., L.M. and P.P.; funding acquisition P.P. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by Istituto Superiore di Sanità, intramural funding “Ricerca Corrente”.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| ABC          | ATP-binding cassette |
| ACOX1        | acyl-CoA oxidase 1 |
| ApoE         | Apolipoprotein E |
| ARSA         | Arylsulfatase A |
BBB  Blood–brain barrier
CNS  Central nervous system
CY27A1  Sterol 27-hydroxylase
DHC  Dehydrocholesterol
DHCR  Dehydrocholesterol reductase
HDL  High-density lipoprotein
HMG CoA  Hydroxymethyl-glutaryl-CoA reductase
HSP70  Heat Shock Protein 70
LCAT  Lecithin–cholesterol acyltransferase
LDL  Low-density lipoprotein
LRP1  Low-density lipoprotein receptor-related protein-1
MAG  Myelin-associated glycoprotein
MBP  Myelin basic protein
mTORC1  Mammalian Target of Rapamycin complex 1
NPC1  Niemann-Pick C1 Protein
NPC2  Niemann-Pick C2 Protein
OL  Oligodendrocyte
OP  Oligodendrocyte precursor cell
OSBP  OxySterol Binding Proteins
PLP  Proteolipid protein
PM  Plasma membrane
PMP22  Peripheral myelin protein 22
PNS  Peripheral nervous system
PSAP  Prosaposin precursor
RE  Endoplasmic reticulum
VapB  Vesicle-associated membrane protein-associated protein B
VLCFA  Very-long-chain fatty acid

References
1. Toledano-Zaragoza, A.; Ledesma, M.D. Addressing Neurodegeneration in Lysosomal Storage Disorders: Advances in Niemann Pick Diseases. *Neuropharmacology* 2020, 171, 107851. [CrossRef] [PubMed]
2. Schuchman, E.H.; Wasserstein, M.P. Types A and B Niemann-Pick Disease. *Best Pract. Res. Clin. Endocrinol. Metab.* 2015, 29, 237–247. [CrossRef] [PubMed]
3. Varier, M.T. Niemann-Pick Disease Type, C. *Orphanet J. Rare Dis.* 2010, 5, 16. [CrossRef] [PubMed]
4. Pallottini, V.; Pfrieger, F.W. Understanding and Treating Niemann–Pick Type C Disease: Models Matter. *Int. J. Mol. Sci.* 2020, 21, 8979. [CrossRef]
5. Lloyd-Evans, E.; Morgan, A.J.; He, X.; Smith, D.A.; Elliot-Smith, E.; Silence, D.J.; Churchill, G.C.; Schuchman, E.H.; Galione, A.; Platt, F.M. Niemann-Pick Disease Type C1 Is a Sphingosine Storage Disease That Causes Deregulation of Lysosomal Calcium. *Nat. Med.* 2008, 14, 1247–1255. [CrossRef]
6. Wheeler, S.; Silence, D.J. Niemann–Pick Type C Disease: Cellular Pathology and Pharmacotherapy. *J. Neurochem.* 2020, 153, 674–692. [CrossRef] [PubMed]
7. Torres, S.; García-Ruiz, C.M.; Fernandez-Checa, J.C. Mitochondrial Cholesterol in Alzheimer’s Disease and Niemann-Pick Type C Disease. *Front. Neurol.* 2019, 10, 1168. [CrossRef]
8. Kennedy, B.E.; LeBlanc, V.G.; Mailman, T.M.; Fice, D.; Burton, I.; Karakach, T.K.; Karten, B. Pre-Symptomatic Activation of Antioxidant Responses and Alterations in Glucose and Pyruvate Metabolism in Niemann-Pick Type C1-Deficient Murine Brain. *PLoS ONE* 2013, 8, e82685. [CrossRef]
9. Yu, T.; Lieberman, A.P. Npc1 Acting in Neurons and Glia Is Essential for the Formation and Maintenance of CNS Myelin. *PLoS Genet.* 2013, 9. [CrossRef]
10. Petrov, A.M.; Kasimov, M.R.; Zefirov, A.L. Brain Cholesterol Metabolism and Its Defects:Linkage to Neurodegenerative Diseases and Synaptic Dysfunction. *Acta Nat.* 2016, 8, 58–73. [CrossRef]
11. Hussain, G.; Wang, J.; Rasul, A.; Anwar, H.; Imran, A.; Qasim, M.; Zafar, S.; Kamran, S.K.S.; Razzaq, A.; Aziz, N.; et al. Role of Cholesterol and Sphingolipids in Brain Development and Neurological Diseases. *Lipids Health Dis.* 2019, 18, 26. [CrossRef] [PubMed]
12. Mathews, E.S.; Appel, B. Cholesterol Biosynthesis Supports Myelin Gene Expression and Axon Ensheathment through Modulation of P13K/Akt/MTor Signaling. *J. Neurosci.* 2016, 36, 7628–7639. [CrossRef]
13. Saher, G.; Brügger, B.; Lappe-Siefke, C.; Möbius, W.; Tozawa, R.; Wehr, M.C.; Wieland, F.; Ishibashi, S.; Nave, K.-A. High Cholesterol Level Is Essential for Myelin Membrane Growth. *Nat. Neurosci.* 2005, 8, 468–475. [CrossRef] [PubMed]
14. Waterham, H.R. Defects of Cholesterol Biosynthesis. *FEBS Lett.* 2006, 580, 5442–5449. [CrossRef]
41. Zhou, Y.; Bazick, H.; Miles, J.R.; Fethiere, A.I.; Salihiv, M.O.A.; Fazio, S.; Tavori, H.; Notterpek, L. A Neutral Lipid-Enriched Diet Improves Myelination and Alleviates Peripheral Nerve Pathology in Neuropathic Mice. Exp. Neurol. 2019, 321, 110301. [CrossRef] [PubMed]

42. Zhou, Y.; Miles, J.R.; Tavori, H.; Lin, M.; Khoshbouei, H.; Borchelt, D.R.; Bazick, H.; Landreth, G.E.; Lee, S.; Fazio, S.; et al. PMP22 Regulates Cholesterol Trafficking and ABCA1-Mediated Cholesterol Efflux. J. Neurosci. 2019, 39, 5404–5418. [CrossRef] [PubMed]

43. Zhou, Y.; Borchelt, D.; Bauson, J.C.; Fazio, S.; Miles, J.R.; Tavori, H.; Notterpek, L. Subcellular Diversion of Cholesterol by Gain-and Loss-of-function Mutations in PMP22. Glia 2020, 68, 2900–2915. [CrossRef]

44. Walterfang, M.; White and Gray Matter Alterations in Adults with Niemann-Pick Disease Type C. Neurology 2010, 75, 49–56. [CrossRef] [PubMed]

45. Davies-Thompson, J.; Vavasour, I.; Scheel, M.; Rauscher, A.; Barton, J.S. Reduced Myelin Water in the White Matter Tracts of Patients with Niemann-Pick Disease Type C. Am. J. Neuroradiol. 2016, 37, 1487–1489. [CrossRef] [PubMed]

46. Weintraub, H.; Abramovici, A.; Sandbank, U.; Booth, A.D.; Pentchev, P.G.; Sela, B. Dysmyelination in NCTR-Balb/C mouse mutant with a lysosomal storage disorder. Acta Neuropathol. 1987, 74, 374–381. [CrossRef]

47. Takikita, S.; Fukuda, T.; Mohri, I.; Yagi, T.; Suzuki, K. Perturbed Myelination Process of Premyelinating Oligodendrocyte in Niemann-Pick Type C Mouse. J. Neuropathol. Exp. Neurol. 2004, 63, 660–673. [CrossRef] [PubMed]

48. Yan, X.; Lukas, J.; Witt, M.; Wree, A.; Hüblner, R.; Frech, M.; Köhling, R.; Rolfs, A.; Luo, J. Decreased Expression of Myelin Gene Regulatory Factor in Niemann-Pick Type C 1 Mouse. Metab. Brain Dis. 2011, 26, 299–306. [CrossRef] [PubMed]

49. Yang, F.; Feng, X.; Rolfs, A.; Luo, J. Lovastatin Promotes Myelin Formation in NPC1 Mutant Oligodendrocytes. J. Neurol. Sci. 2018, 386, 56–63. [CrossRef]

50. Yang, F.; Guan, Y.; Feng, X.; Rolfs, A.; Schlüter, H.; Luo, J. Proteomics of the Corpus Callosum to Identify Novel Factors Involved in Hypomyelinated Niemann-Pick Disease C Mouse. Mol. Brain 2019, 12, 17. [CrossRef] [PubMed]

51. Caporalí, P.; Bruno, E.; Palladino, G.; Dragotto, J.; Petrovsi, L.; Mangia, F.; Erickson, R.P.; Canterini, S.; Fiorenza, M.T. Developmental Delay in Motor Skill Acquisition in Niemann-Pick C1 Mouse reveals Abnormal Cerebellar Morphogenesis. Acta Neuropatol. Commun. 2016, 4, 94. [CrossRef]

52. Bagel, J.H.; Sikora, T.U.; Prociuk, M.; Pesayco, J.P.; Mizisin, A.P.; Shelton, G.D.; Vite, C.H. Electrodiagnostic Testing and Histopathological Changes Confer Peripheral Nervous System Myelin Abnormalities in the Feline Model of Niemann-Pick Disease Type C. J. Neuropathol. Exp. Neurol. 2013, 72, 256–262. [CrossRef]

53. Ishibashi, T.; Dakin, K.A.; Stevens, B.; Lee, P.R.; Kozlov, S.V.; Stewart, C.L.; Fields, R.D. Astrocytes Promote Myelination in Response to Electrical Impulses. Neurology 2006, 49, 825–832. [CrossRef] [PubMed]

54. Domingues, H.S.; Portugal, C.C.; Socodato, R.; Relvas, J.B. Oligodendrocyte, Astrocyte, and Microglia Crosstalk in Myelin Differentiation Induces Mitochondrial Genes and Inhibition of Mitochondrial Function Represses Oligodendroglial Differentiation. J. Biol. Chem. 2014, 289, 143–150. [CrossRef] [PubMed]

55. Gabandé-Rodriguez, E.; Perez-Cañamés, A.; Soto-Huelin, B.; Mitro, D.N.; Sánchez-Redondo, S.; Martinez-Sáez, E.; Venero, C.; Peinado, H.; Ledesma, M.D. Lipid-induced Lysosomal Damage after Demyelination Corrupts Microglia Protective Function in Lysosomal Storage Disorders. EMBO J. 2019, 38, e99553. [CrossRef]

56. Kreher, C.; Favret, J.; Mauilik, M.; Shin, D. Lysosomal Functions in Glia Associated with Neurodegeneration. Biomolecules 2021, 11, 400. [CrossRef]

57. Schoenfeld, R.; Wong, A.; Silva, J.; Li, M.; Itoh, A.; Horiuichi, M.; Itoh, T.; Pleasure, D.; Cortopassi, G. Oligodendroglial Differentiation Induces Mitochondrial Genes and Inhibition of Mitochondrial Function Represses Oligodendroglial Differentiation. Mitochondrion 2018, 29, 104–113. [CrossRef] [PubMed]

58. Torres, S.; Matías, N.; Baulies, A.; Nuñez, S.; Alarcon-Vila, C.; Martinez, L.; Nuñez, M.; Fernandez, A.; Caballeria, J.; Leveda, T.; et al. Mitochondrial GSH Replenishment as a Potential Therapeutic Approach for Niemann-Pick Type C Disease. Oxid. Med. Cell. Longev. 2016, 2016, 1–10. [CrossRef] [PubMed]

59. Kennedy, B.E.; Madreiter, C.T.; Vishnu, N.; Malli, R.; Graier, W.F.; Karten, B. Adaptations of Energy Metabolism Associated with Increased Levels of Mitochondrial Cholesterol in Niemann-Pick Type C1-Deficient Cells. J. Biol. Chem. 2014, 289, 16278–16289. [CrossRef] [PubMed]

60. Yu, W.; Gong, J.-S.; Ko, M.; Garver, W.S.; Yanagisawa, K.; Michikawa, M. Altered Cholesterol Metabolism in Niemann-Pick Type C1 Mouse Brains Affects Mitochondrial Function. J. Biol. Chem. 2005, 280, 11731–11739. [CrossRef] [PubMed]

61. Visentin, S.; De Nuccio, C.; Bernardo, A.; Pepponi, R.; Ferrante, A.; Minghetti, L.; Popoli, P. The Stimulation of Adenosine A2A Receptors Ameliorates the Pathological Phenotype of Fibroblasts from Niemann-Pick Type C Patients. J. Neurosci. 2013, 33, 15388–15393. [CrossRef] [PubMed]

62. De Nuccio, C.; Bernardo, A.; Ferrante, A.; Pepponi, R.; Martire, A.; Falchi, M.; Visentin, S.; Popoli, P.; Minghetti, L. Adenosine A2A Receptor Stimulation Restores Cell Functions and Differentiation in Niemann-Pick Type C-like Oligodendrocytes. Sci. Rep. 2019, 9, 1–10. [CrossRef] [PubMed]

63. Colacurcio, D.J.; Dixon, R.A. Disorders of Lysosomal Acidification-The Emerging Role of v-ATPase in Aging and Neurodegenerative Disease. Ageing Res. Rev. 2016, 32, 75–88. [CrossRef] [PubMed]
66. Kiselyov, K.K.; Ahuja, M.; Rybalchenko, V.; Patel, S.; Muallem, S. The Intracellular Ca2+ Channels of Membrane Traffic. *Channels* 2012, 6, 344–351. [CrossRef] [PubMed]

67. Buratta, S.; Tancini, B.; Sagini, K.; Delo, F.; Chiaradia, E.; Urbanelli, L.; Emiliani, C. Lysosomal Exocytosis, Exosome Release and Secretory Autophagy: The Autophagic- and Endo-Lysosomal Systems Go Extracellular. *Int. J. Mol. Sci.* 2020, 21, 2576. [CrossRef]

68. Davis, O.B.; Shin, H.R.; Lim, C.-Y.; Wu, E.Y.; Kuukurruga, M.; Maher, C.F.; Perera, R.M.; Ordonez, M.P.; Zoncu, R. NPC1-MTORC1 Signaling Couples Cholesterol Sensing to Organelle Homeostasis and Is a Targetable Pathway in Niemann-Pick Type C. *Dev. Cell* 2021, 56, 260–276. [CrossRef] [PubMed]

69. Castellano, B.M.; Thelen, A.M.; Moldavski, O.; Feltes, M.; van der Welle, R.E.N.; Mydock-McGrane, L.; Jiang, X.; van Eijkeren, R.J.; Davis, O.B.; Louie, S.M.; et al. Lysosomal Cholesterol Activates MTORC1 via an SLC38A9–Niemann-Pick C1 Signaling Complex. *Science* 2017, 355, 1306–1311. [CrossRef] [PubMed]

70. Bankston, A.N.; Forston, M.D.; Howard, K.R.; Smith, A.E.; Ohri, S.S.; Bates, M.L.; Bunge, M.B.; Whittemore, S.R. Autophagy Is Essential for Oligodendrocyte Differentiation, Survival, and Proper Myelination. *Glia* 2019, 67, 1745–1759. [CrossRef]

71. Lebrun-Julien, F.; Bachmann, L.; Norrmén, C.; Trötzmüller, M.; Köfeler, H.; Rüegg, M.A.; Hall, M.N.; Suter, U. Balanced MTORC1 Activity in Oligodendrocytes Is Required for Accurate CNS Myelination. *J. Neurosci*. 2014, 34, 8432–8448. [CrossRef]

72. Figlia, G.; Gerber, D.; Suter, U. Myelination and MTOR. *Glia* 2018, 66, 693–707. [CrossRef] [PubMed]

73. Platt, F.M.; Neises, G.R.; Karlsson, G.B.; Dwek, R.A.; Butters, T.D. N-Butyldeoxygalactonojirimycin Inhibits Glycolipid Biosynthesis but Does Not Affect N-Linked Oligosaccharide Processing. *J. Biol. Chem.* 1994, 269, 27108–27114. [CrossRef]

74. Kirkegaard, T.; Gray, J.; Priestman, D.A.; Wallom, K.L.; Atkins, J.; Olsen, O.D.; Klein, A.; Drndarski, S.; Petersen, N.H.; Ingemann, L.; et al. Heat Shock Protein-Based Therapy as a Potential Candidate for Treating the Sphingolipidoses. *Sci. Transl. Med.* 2016, 8, 355ra118. [CrossRef] [PubMed]

75. Pipalia, N.H.; Cosner, C.C.; Huang, A.; Chatterjee, A.; Bourbon, P.; Farley, N.; Helquist, P.; Wiest, O.; Maxfield, F.R. Histone Deacetylase Inhibitor Treatment Dramatically Reduces Cholesterol Accumulation in Niemann-Pick Type C1 Mutant Human Fibroblasts. *Proc. Natl. Acad. Sci. USA* 2011, 108, 5620–5625. [CrossRef] [PubMed]

76. Pineda, M.; Wraith, J.E.; Mengel, E.; Sedel, F.; Hwu, W.-L.; Rohrbach, M.; Bembi, B.; Walterfang, M.; Korenke, G.C.; Marquardt, T. Miglustat in Patients with Niemann-Pick Disease Type C (NP-C): A Multicenter Observational Retrospective Cohort Study. *Mol. Genet. Metab.* 2009, 98, 243–249. [CrossRef] [PubMed]

77. Platt, F.M. Emptying the Stores: Lysosomal Diseases and Therapeutic Strategies. *Nat. Rev. Drug Discov.* 2018, 17, 133–150. [CrossRef] [PubMed]

78. Patterson, M.C.; Vecchio, D.; Prady, H.; Abel, L.; Wraith, J.E. Miglustat for Treatment of Niemann-Pick C Disease: A Randomised Controlled Study. *Lancet Neurol.* 2007, 6, 765–772. [CrossRef]

79. Belmatoug, N.; Burlina, A.; Giraldo, P.; Hendriksz, C.J.; Kuter, D.J.; Mengel, E.; Pastores, G.M. Gastrointestinal Disturbances and Their Management in Miglustat-Treated Patients. *J. Inherit. Metab. Dis.* 2011, 34, 991–1001. [CrossRef] [PubMed]

80. Patterson, M.C.; Mengel, E.; Vanier, M.T.; Moneuse, P.; Rosenberg, D.; Pineda, M. Treatment Outcomes Following Continuous Miglustat Therapy in Patients with Niemann-Pick Disease Type C: A Final Report of the NPC Registry. *Orphanet J. Rare Dis.* 2020, 15, 104. [CrossRef]

81. Scheel, M.; Abegg, M.; Lanyon, L.J.; Mattman, A.; Barton, J.J. Eye Movement and Diffusion Tensor Imaging Analysis of Treatment Effects in a Niemann—Pick Type C1 Mutant. *J. Neurosci. Res.* 2008, 86, 2802–2807. [CrossRef]

82. Li, B.; Li, H.; Repa, J.J.; Turley, S.D.; Dietschy, J.M. Genetic Variations and Treatments That Affect the Lifespan of the NPC1 Mice. *J. Lipid Res.* 2008, 49, 663–669. [CrossRef]

83. Feltes, M.; Gale, S.E.; Moores, S.; Ory, D.S.; Schaffer, J.E. Monitoring the Itinerary of Lysosomal Cholesterol in Niemann-Pick Type C1-Deficient Cells after Cycloheximide Treatment. *J. Lipid Res.* 2020, 61, 403–412. [CrossRef] [PubMed]

84. Hastings, C.; Vieira, C.; Lopes-Piedrafita, S.; Totenhagen, J.W.; Hicks, C.M.; Erickson, R.P.; Trouard, T.P. MRI Detects Therapeutic Effects in Weanling Niemann-Pick Type C1 Mice. *Mol. Genet. Metab.* 2018, 23, 6231–6238. [CrossRef] [PubMed]

85. Lope-Piedrafita, S.; Totenhagen, J.W.; Hicks, C.M.; Erickson, R.P.; Trouard, T.P. MRI Detects Therapeutic Effects in Weanling Niemann-Pick Type C1 Mice. *J. Neurosci.* 2008, 36, 2802–2807. [CrossRef]

86. Chandler, R.J.; Williams, I.M.; Gibson, A.L.; Davidson, C.D.; Incao, A.A.; Hubbard, B.T.; Porter, F.D.; Pavan, W.J.; Venditti, C.P. Systemic AA V9 Gene Therapy Improves the Lifespan of Mice with Niemann-Pick Disease, Type C1. *Hum. Mol. Genet.* 2017, 26, 52–64. [CrossRef] [PubMed]
91. Xie, C.; Gong, X.M.; Luo, J.; Li, B.L.; Song, B.L. AAV9-NPC1 Significantly Ameliorates Purkinje Cell Death and Behavioral Abnormalities in Mouse NPC Disease. *J. Lipid Res.* **2017**, *58*, 512–518. [CrossRef] [PubMed]

92. Hughes, D.A.; Smith, L.; Morris, C.; Fletcher, A.; Colaco, M.; Huebecker, J.; Tordo, N.; Palomar, G.; Massaro, E.; Henckaerts, S.N.; et al. Rahim AAV9 Intracerebroventricular Gene Therapy Improves Lifespan, Locomotor Function and Pathology in a Mouse Model of Niemann-Pick Type C1 Disease. *Hum. Mol. Genet.* **2018**, *27*, 3079–3098. [CrossRef]

93. Kaya, E.; Smith, D.A.; Smith, C.; Morris, L.; Bremova-Ertl, T.; Cortina-Borja, M.; Fineran, P.; Morten, K.J.; Poulton, J.; Boland, B.; et al. Acetyl-Leucine Slows Disease Progression in Lysosomal Storage Disorders. *Brain Commun.* **2021**, *3*, fca148. [CrossRef]

94. Park, D.; Shin, K.; Choi, E.-K.; Choi, Y.; Jang, J.-Y.; Kim, J.; Jeong, H.-S.; Lee, W.; Lee, Y.-B.; Kim, S.U.; et al. Protective Effects of N-Acetyl-L-Cysteine in Human Oligodendrocyte Precursor Cells and Restoration of Motor Function in Neonatal Rats with Hypoxic-Ischemic Encephalopathy. *Evid. Based Complement. Altern. Med.* **2015**, *2015*, 764251. [CrossRef] [PubMed]

95. Griffin, L.D.; Gong, W.; Verot, L.; Mellon, S.H. Niemann—Pick Type C Disease Involves Disrupted Neurosteroidogenesis and Responds to Allopregnanolone. *Nat. Med.* **2004**, *10*, 704–711. [CrossRef]

96. Mellon, S.H.; Gong, W.; Schonemann, M.D. Endogenous and Synthetic Neurosteroids in Treatment of Niemann–Pick Type C Disease. *Brain Res. Rev.* **2008**, *57*, 410–420. [CrossRef] [PubMed]

97. Holzmann, C.; Witt, M.; Rolfs, A.; Antipova, V.; Wree, A. Gender-Specific Effects of Two Treatment Strategies in a Mouse Model of Niemann-Pick Disease Type C1. *Int. J. Mol. Sci.* **2021**, *22*, 2539. [CrossRef] [PubMed]

98. Ahmad, I.; Lope-Piedrafita, S.; Bi, X.; Hicks, C.; Yao, Y.; Yu, C.; Chaitkin, E.; Howison, C.M.; Weberg, L.; Trouard, T.P.; et al. Allopregnanolone Treatment, Both as a Single Injection or Repetitively, Delays Demyelination and Enhances Survival of Niemann-Pick C Mice. *J. Neurosci. Res.* **2005**, *82*, 811–821. [CrossRef]

99. Davidson, C.D.; Ali, N.F.; Micsenyi, M.C.; Stephney, G.; Renault, S.; Dobrenis, K.; Ory, D.S.; Vanier, M.T.; Walkley, S.U. Chronic Allopregnanolone Treatment, Both as a Single Injection or Repetitively, Delays Demyelination and Enhances Survival of Niemann-Pick C Mice. *J. Neurosci. Res.* **2005**, *82*, 811–821. [CrossRef]

100. Gomes, C.V.; Kaster, M.P.; Tomé, A.R.; Agostinho, P.M.; Cunha, R.A. Adenosine Receptors and Brain Diseases:Neuroprotection and Neurodegeneration. *Biochim. Biophys. Acta Biomembr.* **2011**, *1808*, 1380–1399. [CrossRef]

101. Sachdeva, S.; Gupta, M. Adenosine and Its Receptors as Therapeutic Targets:An Overview. *Saudi Pharm. J.* **2013**, *21*, 245–253. [CrossRef]

102. Klinger, M.; Freissmuth, M.; Nanoff, C. Adenosine Receptors:G Protein-Mediated Signalling and the Role of Accessory Proteins. *Cell. Signal.* **2002**, *14*, 99–108. [CrossRef]

103. Carpenter, B.; Lebon, G. Human Adenosine A2A Receptor:Molecular Mechanism of Ligand Binding and Activation. *Front. Pharmacol.* **2017**, *8*, 898. [CrossRef] [PubMed]

104. Chen, J.-F.; Sonsalla, P.K.; Pedata, F.; Melani, A.; Domenici, M.R.; Popoli, P.; Geiger, J.; Lopes, L.V.; de Mendonça, A. Adenosine A2A Receptors and Brain Injury:Broad Spectrum of Neuroprotection, Multifaceted Actions and “Fine Tuning” Modulation. *Prog. Neurobiol.* **2007**, *83*, 310–331. [CrossRef]

105. Popoli, P.; Pintor, A.; Domenici, M.R.; Frank, C.; Tebano, M.T.; Pezzola, A.; Sarchielli, L.; Quarta, D.; Reggio, R.; Malchiodi-Albedi, F.; et al. Blockade of Striatal Adenosine A2A Receptor Reduces, through a Presynaptic Mechanism, Quinolinic Acid-Induced Excitotoxicity:Possible Relevance to Neuroprotective Interventions in Neurodegenerative Diseases of the Striatum. *J. Neurosci.* **2002**, *22*, 1967–1975. [CrossRef] [PubMed]

106. Popoli, P.; Blum, D.; Martire, A.; Ledent, C.; Ceruti, S.; Abbraccchio, M. Functions, Dysfunctions and Possible Therapeutic Relevance of Adenosine A2A Receptors in Huntington’s Disease. *Prog. Neurobiol.* **2007**, *81*, 331–348. [CrossRef] [PubMed]

107. Popoli, P.; Blum, D.; Domenici, M.R.; Burnouf, S.; Chern, Y. A Critical Evaluation of Adenosine A2A Receptors as Potentially “Druggable” Targets in Huntington’s Disease. *Curr. Pharm. Des.* **2008**, *14*, 1500–1511. [CrossRef]

108. Stockwell, J.; Jakova, E.; Cayabayab, F.S. Adenosine A1 and A2A Receptors in the Brain:Current Research and Their Role in Neurodegeneration. *Molecules* **2017**, *22*, 667. [CrossRef]

109. Lee, C.-C.; Chang, C.-P.; Lin, C.-J.; Lai, H.-L.; Kao, Y.-H.; Cheng, S.-J.; Chen, H.-M.; Liao, Y.-P.; Faivre, E.; Buée, L.; et al. Adenosine Augmentation Evoked by an ENT1 Inhibitor Improves Memory Impairment and Neuronal Plasticity in the APP/PS1 Mouse Model of Alzheimer’s Disease. *Mol. Neurobiol.* **2018**, *55*, 8936–8952. [CrossRef]

110. Kao, Y.-H.; Lin, M.-S.; Chen, C.-M.; Wu, Y.-R.; Chen, H.-M.; Lai, H.-L.; Chern, Y.; Lin, C.-J. Targeting ENT1 and Adenosine Tone for the Treatment of Huntington’s Disease. *Hum. Mol. Genet.* **2017**, *26*, ddw402. [CrossRef]

111. Cherchi, F.; Pugliese, A.; Coppi, E. Oligodendrocyte Precursor Cell Maturation:Role of Adenosine Receptors. *Neural Regen. Res.* **2021**, *16*, 1686–1692. [CrossRef]

112. Coppi, E.; Cellai, L.; Maraula, G.; Pugliese, A.M.; Pedata, F. Adenosine A2A Receptors Inhibit Delayed Rectifier Potassium Currents and Cell Differentiation in Primary Purified Oligodendrocyte Cultures. *Neuropharmacology* **2013**, *73*, 301–310. [CrossRef]

113. Fontenas, L.; Welsh, T.G.; Piller, M.; Coughenour, P.; Gandhi, A.V.; Prober, D.A.; Kucenas, S. The Neuromodulator Adenosine Regulates Oligodendrocyte Migration at Motor Exit Point Transition Zones. *Cell Rep.* **2019**, *27*, 115–128.e5. [CrossRef] [PubMed]

114. Zhou, S.; Xu, S.; Yan, Y.; Yu, H.; Ling, S.; Luo, J. Decreased Purinergic Inhibition of Synaptic Activity in a Mouse Model of Niemann-Pick Disease Type C. *Hippocampus* **2011**, *21*, 212–219. [CrossRef]

115. Ferrante, A.; De Nuccio, C.; Pepponi, R.; Visentin, S.; Martire, A.; Bernardi, A.; Minghetti, L.; Popoli, P. Stimulation of Adenosine A2A Receptors Reduces Intracellular Cholesterol Accumulation and Rescues Mitochondrial Abnormalities in Human Neural Cell Models of Niemann-Pick C1. *Neuropharmacology* **2016**, *103*, 155–162. [CrossRef] [PubMed]
116. Ferrante, A.; Pezzola, A.; Matteucci, A.; Di Biase, A.; Attorri, L.; Armida, M.; Martire, A.; Chern, Y.; Popoli, P. The Adenosine $A_{2A}$ Receptor Agonist T1–11 Ameliorates Neurovisceral Symptoms and Extends the Lifespan of a Mouse Model of Niemann-Pick Type C Disease. *Neurobiol. Dis.* 2018, 110, 1–11. [CrossRef]

117. Wojtanik, K.M.; Liscum, L. The Transport of Low Density Lipoprotein-Derived Cholesterol to the Plasma Membrane Is Defective in NPC1 Cells. *J. Biol. Chem.* 2003, 278, 14850–14856. [CrossRef] [PubMed]

118. McGraw, C.; Yang, L.; Levental, I.; Lyman, E.; Robinson, A.S. Membrane Cholesterol Depletion Reduces Downstream Signaling Activity of the Adenosine $A_{2A}$ Receptor. *Biochim. Biophys. Acta Biomembr.* 2019, 1861, 760–767. [CrossRef] [PubMed]

119. Martire, A.; Calamandrei, G.; Felici, F.; Scattoni, M.L.; Lastoria, G.; Domenici, M.R.; Tebano, M.T.; Popoli, P. Opposite Effects of the $A_{2A}$ Receptor Agonist CGS21680 in the Striatum of Huntington’s Disease versus Wild-Type Mice. *Neurosci. Lett.* 2007, 417, 78–83. [CrossRef]

120. Fog, C.K.; Kirkegaard, T. Animal Models for Niemann-Pick Type C: Implications for Drug Discovery & Development. *Expert Opin. Drug Discov.* 2019, 14, 499–509. [CrossRef]